Johnson & Johnson logo

Johnson & Johnson (JNJ)

Market Closed
24 Feb, 15:30
XETRA XETRA
209. 15
+0.25
+0.12%
356.43B Market Cap
29.06 P/E Ratio
1.34% Div Yield
1,112 Volume
9.91 Eps
208.9
Previous Close
Day Range
206.85 209.85
Year Range
128.16 210.65
Want to track JNJ and more in your Portfolio? 🎯
Sign up for Marketlog, a portfolio tracker that will exceed your expectations!
JNJ earnings report is expected in 48 days (13 Apr 2026)

Summary

JNJ closed today higher at €209.15, an increase of 0.12% from yesterday's close, completing a monthly increase of 18.7% or €32.95. Over the past 12 months, JNJ stock gained 18.7%.
JNJ pays dividends to its shareholders, with the most recent payment made on Dec 09, 2025. The next announced payment will be in In 2 weeks on Mar 10, 2026 for a total of €1.3.
The last earnings report, released on Jan 21, 2026, missed the consensus estimates by -0.67%. On average, the company has fell short of earnings expectations by -0.76%, based on the last three reports. The next scheduled earnings report is due on Apr 13, 2026.
Johnson & Johnson has completed 1 stock splits, with the recent split occurring on Jun 13, 2001.
The company's stock is traded on 19 different exchanges and in various currencies, with the primary listing on NYSE (USD).

JNJ Chart

Boring Is Beautiful: Why Johnson & Johnson Is Beating the Tech Sector

Boring Is Beautiful: Why Johnson & Johnson Is Beating the Tech Sector

While the technology sector faces a renewed wave of volatility driven by artificial intelligence (AI) scare trades and valuation concerns, a different story is unfolding in the healthcare sector. Investors fleeing the jittery price swings of high-growth tech stocks are finding shelter in a familiar name that is quietly outperforming.

Marketbeat | 2 hours ago
Wall Street Bulls Look Optimistic About Johnson & Johnson (JNJ): Should You Buy?

Wall Street Bulls Look Optimistic About Johnson & Johnson (JNJ): Should You Buy?

The recommendations of Wall Street analysts are often relied on by investors when deciding whether to buy, sell, or hold a stock. Media reports about these brokerage-firm-employed (or sell-side) analysts changing their ratings often affect a stock's price.

Zacks | 8 hours ago
Why Is Johnson & Johnson (JNJ) Up 13% Since Last Earnings Report?

Why Is Johnson & Johnson (JNJ) Up 13% Since Last Earnings Report?

Johnson & Johnson (JNJ) reported earnings 30 days ago. What's next for the stock?

Zacks | 4 days ago

Johnson & Johnson (JNJ) FAQ

What is the stock price today?

The current price is €209.15.

On which exchange is it traded?

Johnson & Johnson is listed on XETRA.

What is its stock symbol?

The ticker symbol is JNJ.

Does it pay dividends? What is the current yield?

Yes, It pays dividends and the current yield is 1.34%.

What is its market cap?

As of today, the market cap is 356.43B.

When is the next earnings date?

The next earnings report will release on Apr 13, 2026.

Has Johnson & Johnson ever had a stock split?

Johnson & Johnson had 1 splits and the recent split was on Jun 13, 2001.

Johnson & Johnson Profile

Media Industry
Communication Services Sector
Joaquin Duato CEO
XETRA Exchange
US4781601046 ISIN
US Country
138,100 Employees
10 Mar 2026 Last Dividend
13 Jun 2001 Last Split
- IPO Date

Overview

Johnson & Johnson, a renowned entity in the healthcare sector, operates globally with a broad focus on research, development, manufacturing, and sales of healthcare products. The company is structured in multiple segments, primarily Innovative Medicine and MedTech, catering to a vast array of therapeutic areas and medical needs. Founded in 1886, the company is headquartered in New Brunswick, New Jersey, illustrating a longstanding presence and commitment to healthcare innovation and advancement. Through its extensive product line and diversified service offerings, Johnson & Johnson reaches a wide audience, including retailers, wholesalers, distributors, hospitals, and healthcare professionals, providing prescription and non-prescription products alike.

Products and Services

The company's portfolio is divided into two main segments, each encompassing a variety of products and services designed to meet the complex demands of modern healthcare:

  • Innovative Medicine:

    This segment includes a range of products for different therapeutic areas. These encompass immunology (covering diseases like rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis), infectious diseases (including HIV/AIDS treatment), neuroscience (targeting mood disorders, neurodegenerative disorders, schizophrenia), oncology (focused on cancers such as prostate, lung, bladder, and hematologic malignancies), cardiovascular and metabolism (addressing conditions like thrombosis, diabetes, and macular degeneration), and pulmonary hypertension, specifically pulmonary arterial hypertension.

  • MedTech:

    This segment offers products and technologies across a range of medical fields. Interventional Solutions include electrophysiology products for heart rhythm disorders and technologies for severe coronary artery disease treatment. The neurovascular care line focuses on treating hemorrhagic and ischemic strokes. Orthopaedics products support treatments for hips, knees, trauma, spine, and sports injuries. The surgery portfolio covers advanced and general surgery technologies and solutions for breast aesthetics and ear, nose, and throat procedures. Additionally, MedTech offers visual health products like ACUVUE Brand contact lenses and TECNIS intraocular lenses for cataract surgery.

Contact Information

Address: One Johnson & Johnson Plaza
Phone: 732 524 0400